Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 2/20 | 0.31 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.31 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.31 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31272081 | 0.81 | F2 (0.31) | F2PRSS1PRSS2PRSS3ALDH1A1 | |
| SCHEMBL10638964 | 0.76 | — | — | |
| SCHEMBL751015 | 0.76 | — | — | |
| SCHEMBL25877715 | 0.75 | ALDH1A1 (0.30) | ALDH1A1TP53TSHR | |
| SCHEMBL11724639 | 0.73 | ALDH1A1 (0.33) | ALDH1A1TP53TSHR | |
| SCHEMBL3503299 | 0.73 | ALDH1A1 (0.33) | ALDH1A1TP53TSHR | |
| SCHEMBL10454353 | 0.71 | ALDH1A1 (0.47) | ALDH1A1TP53TSHR | |
| Trifluoroacetamide SCHEMBL20915034 | 0.71 | ALDH1A1 (0.39) | ALDH1A1TP53TSHR | |
| SCHEMBL28203079 | 0.71 | ALDH1A1 (0.32) | ALDH1A1TP53TSHR | |
| SCHEMBL15993915 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234921-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | ASCLETIS BIOSCIENCE CO., LTD. (CN) | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234921-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | SERPINB1, CTSV, CTSE | F2 1445/4885PRSS1 20/4885PRSS2 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.